# Eupraxia Pharmaceuticals Inc. (EPRX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $6.88, market value $455 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Eupraxia Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.4×**. The shares trade at 4.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -8.1%** (5-yr avg -18.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -47.9%**. Return on equity is negative because earnings are negative.
- **Return on assets: -45.6%**. Each dollar of assets produces -45.6% of profit.

## Growth
- **EPS growth (1 yr): -45.8%**. Earnings per share fell 45.8%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 2.1×**. It would take 2.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 15.12** (quick 15.12). Current assets cover the next year's liabilities 15.12 times.
- **Altman Z-score: 48.84**. A Z-score of 48.84 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Eupraxia Pharmaceuticals Inc. does not currently pay a dividend, but it returned -24.8% of its market value through buybacks over the last year.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Eupraxia Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $16.61 (+141% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 22.0%** (YTD -10.5%, 3-mo 3.8%). The shares are up 22.0% over twelve months including dividends.
- **From 52-week high: -26.2%** (31.0% above the low). Trading 26% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): 1.57** (volatility 67%). Beta of 1.57 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EPRX · Page: https://foliofundamentals.com/stocks/eprx

Not investment advice.